Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC

NCT04278547 is registered in ClinicalTrials.gov with Hospital Universitari de Bellvitge as lead sponsor.

NCT NCT04278547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC
Lead sponsor
Hospital Universitari de Bellvitge
Phase
Phase 4
Overall status
Unknown status
Start date
June 12, 2020
Completion date
March 25, 2023
Enrollment
188 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cmv infection, heart transplant infection